Hydrocortison Tiofarma (Hydrocortisone)

Hydrocortison Tiofarma is prescribed for conditions that require cortisol replacement or anti‑inflammatory therapy.

• Primary adrenal insufficiency (Addison’s disease) where endogenous cortisol production is inadequate.
• Congenital adrenal hyperplasia requiring glucocorticoid supplementation.
• Acute or chronic inflammatory disorders such as rheumatoid arthritis, systemic lupus erythematosus, or severe dermatitis.
• Autoimmune conditions where immunosuppression is needed, for example inflammatory bowel disease or multiple sclerosis relapses.
• Situations of adrenal crisis or stress dosing in patients on long‑term glucocorticoid therapy.

• Hydrocortisone acts as an agonist at intracellular glucocorticoid receptors. After crossing cell membranes, the drug‑receptor complex translocates to the nucleus, where it binds glucocorticoid response elements and modulates gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and suppression of the immune response, thereby providing cortisol replacement and anti‑inflammatory effects. Additionally, it promotes the expression of anti‑inflammatory proteins such as annexin‑1.

Like all glucocorticoids, hydrocortisone may cause a range of adverse reactions that vary in frequency and severity.

Common

• Increased appetite and weight gain.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels, especially in diabetic patients.
• Mood changes such as irritability or insomnia.
• Gastrointestinal discomfort, including nausea or dyspepsia.

Serious

• Suppression of the hypothalamic‑pituitary‑adrenal axis, risking adrenal insufficiency on abrupt withdrawal.
• Severe hypertension or worsening of pre‑existing cardiovascular disease.
• Opportunistic infections due to immunosuppression.
• Osteoporosis or increased risk of fractures with long‑term use.
• Peptic ulcer disease or gastrointestinal bleeding.

Before initiating Hydrocortison Tiofarma, clinicians should evaluate several safety considerations to minimize risk.

• Assess adrenal function and confirm the need for glucocorticoid replacement.
• Screen for uncontrolled diabetes, hypertension, or active infections.
• Use the lowest effective dose for the shortest duration possible.
• Monitor bone density in patients requiring long‑term therapy.
• Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal crisis.
• Caution in pregnant or breastfeeding women, as safety data are limited.
• Review concomitant medications that may increase glucocorticoid exposure.

Hydrocortisone can affect the pharmacokinetics or pharmacodynamics of several other agents.

Avoid

• Strong CYP3A4 inducers such as rifampin, which may reduce hydrocortisone levels.
• High‑dose systemic corticosteroids combined with other immunosuppressants without medical supervision.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may increase the risk of gastrointestinal ulceration.
• Anticoagulants (e.g., warfarin), as glucocorticoids can alter INR values.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.
• Diabetic medications, because hydrocortisone may raise blood glucose.